Kirilys Therapeutics, a California-based biotechnology company announced the completion of its Series A investment from Global Brain Corporation, a Japan-based early-staged focused venture capital firm.

Kirilys Therapeutics, Inc. is a private, preclinical-stage biopharmaceutical company committed to the development of multiple precision oncology assets. Kirilys’ initial asset is KRLS-017, a novel CDK7 inhibitor with the potential to improve the treatment of multiple cancers. Kirilys is headquartered in San Francisco, CA.